| Outcome Measures: |
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Assessment by adverse event monitoring, 12 lead ECGs, vital signs and laboratory measurements., First dose of study drug up to 29 days after last dose of study drug | Secondary: Area Under the Curve From Time Zero to Last Quantifiable Concentration, Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast), Pre dose and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 72, 168 (day 8), 336 (day 15), 504(day 22), 672 (day 29) hours following single dose administration;|Maximum Observed Plasma Concentration (Cmax), Maximum Observed Plasma Concentration (Cmax), Pre dose and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 72, 168 (day 8), 336 (day 15), 504(day 22), 672 (day 29) hours following single dose administration;|Time to Reach Maximum Observed Plasma Concentration (Tmax), Time to Reach Maximum Observed Plasma Concentration (Tmax), Pre dose and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 72, 168 (day 8), 336 (day 15), 504(day 22), 672 (day 29) hours following single dose administration;|Plasma Decay Half-Life (t1/2), Plasma decay half-life is the time measured for the plasma concentration to decrease by one half., Pre dose and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 72, 168 (day 8), 336 (day 15), 504(day 22), 672 (day 29) hours following single dose administration;|Inhibition Rate of Dipeptidyl Peptidase 4 (DPP4) Activities following single dose administration, Inhibition Rate of Dipeptidyl Peptidase 4 (DPP4) Activities following single dose administration, Pre dose and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 72, 168 (day 8), 336 (day 15), 504(day 22), 672 (day 29) hours following single dose administration;
|
